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Bypassing the requirement for aminoacyl-tRNA by
a cyclodipeptide synthase enzyme†
Christopher J. Harding, a Emmajay Sutherland, a Jane G. Hanna, b
Douglas R. Houston c and Clarissa M. Czekster *a
Cyclodipeptide synthases (CDPSs) produce a variety of cyclic dipeptide products by utilising two
aminoacylated tRNA substrates. We sought to investigate the minimal requirements for substrate usage
in this class of enzymes as the relationship between CDPSs and their substrates remains elusive. Here,
we investigated the Bacillus thermoamylovorans enzyme, BtCDPS, which synthesises cyclo(L-Leu–L-
Leu). We systematically tested where specificity arises and, in the process, uncovered small molecules
(activated amino esters) that will suffice as substrates, although catalytically poor. We solved the
structure of BtCDPS to 1.7 Å and combining crystallography, enzymatic assays and substrate docking
experiments propose a model for how the minimal substrates interact with the enzyme. This work is the
first report of a CDPS enzyme utilizing a molecule other than aa-tRNA as a substrate; providing insights
into substrate requirements and setting the stage for the design of improved simpler substrates.
Introduction
Cyclodipeptide synthases (CDPS) are a family of tRNA dependant
enzymes that synthesise cyclic dipeptides using two amino-
acylated tRNA (aa-tRNA) as substrates.1–3 Cyclic dipeptides are
members of a large variety of 2,5-diketopiperazine-containing
natural products, which can be synthesized via non-ribosomal
peptide synthetases or using CDPS enzymes.4,5 They are pro-
duced by organisms in all domains of life, and thought to
interfere with interspecies and interkingdom relationships,
albeit by unknown mechanisms.6,7 Importantly, cyclic dipeptides
possess a privileged chemical structure, conferring high protease
and temperature stability, easy absorption by the gut and the
ability to cross the blood brain barrier, all invaluable therapeutic
traits.4 Important biological activities have been described for
several cyclic dipeptides, including antifungal,9 antibacterial,10
antitumor,11 antiviral,12 immunosuppressant13 and quorum
sensing properties.14 Once produced, cyclic dipeptides can be
highly modified by tailoring enzymes to produce more complex
natural products such as mycocyclosin15 and bicyclomycin,16,17
amongst others.5
CDPS were first identified in 2002 and have since received
much attention.18 All CDPS structurally characterised to date
share a single ab domain containing a Rossmann fold.19–22
They are structurally related to the catalytic domain of class-Ic
aa-tRNA synthetases, such as tyrosyl- and tryptophanyl-tRNA
synthetases, suggesting an evolutionary link.21 However, CDPS
differ significantly from class-Ic aa-tRNA synthetases by lacking
an ATP-binding motif and function as active monomers, rather
than homodimers. The structures of CDPS enzymes have two
deep solvent accessible pockets (P1 and P2), neighbouring the
catalytic site, believed to accommodate the aminoacyl moiety of
aa-tRNA substrates (Fig. 1C and D).23
The catalytic mechanism for these enzymes has been well
documented. CDPS use two aa-tRNA substrates in a ping-pong
mechanism, which forms two successive acyl–enzyme
intermediates.19–21,24 The aminoacyl moiety of tRNA is transferred
onto the conserved active site serine residue (S33 in BtCDPS,
Fig. 1D), forming an aminoacyl-enzyme intermediate.19–21,25 This
intermediate then reacts with a second aa-tRNA to form a
dipeptidyl-enzyme intermediate, which undergoes intramolecular
cyclisation aided by a conserved tyrosine residue to form a cyclic
dipeptide.23,26
CDPS are fairly promiscuous enzymes that predominantly
synthesise one main cyclodipeptide product and several other
cyclodipeptides to a lesser extent.2 Typically, CDPS favour a
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single aminoacyl moiety, which is accommodated in the P1
binding pocket and have less specificity for the second sub-
strate, which binds less stringently into the shallower P2
pocket. For instance, the major product of AlbC from Strepto-
myces noursei is cFL, although significant amounts of cFX
(where X represents another amino acid) are also produced.
Additionally, Rv2275 from Mycobacterium tuberculosis predomi-
nantly synthesises cYY, yet other cYX products are possible.1,2
The residues lining the P1 and P2 pockets confer specificity for
the substrates, which has allowed early prediction of the
cyclodipeptide produced with limited success.1,2 Binding of
the tRNA moiety is thought to be less important to substrate
selection, where patches of charged residues on the surface of
CDPS are predicted to facilitate binding.20,21 However, prefer-
ence towards different tRNALeu isoacceptors by AlbC led to
speculation that specific base pairing on the acceptor stem
may also be essential for recognition.24 A recent study provided
important insights into the interaction between protein and aa-
tRNA.27 However, the mechanism by which CDPS select and
recognise their specific set of substrates from the pools of
aa-tRNA remains ambiguous as a high resolution enzyme-
substrate complex is still lacking.
Here, we investigated a CDPS from Bacillus thermoamylovorans
(BtCDPS), a cLL-synthesising enzyme that utilises Leu-tRNALeu as
a substrate, and is predicted to be part of the biosynthetic
machinery involved in pulcherrimin biosynthesis.20 We set out
to explore the minimal requirements for substrate usage by
systematically testing whether the aminoacyl moiety, the tRNA
moiety or both are fundamental for catalysis. In the process we
uncovered that a small molecule – an activated amino ester – will
suffice as a substrate. This work is the first report of a CDPS
enzyme utilizing a small molecule as a substrate. Our work
provides crucial insights into substrate requirements and lays
the foundation for the design of simpler substrates as well as
CDPS enzyme variants with improved catalytic properties using
minimal substrates.
Fig. 1 Structure of BtCDPS (A) The overall structure BtCDPS in ribbon form, alpha-helices (blue), beta-strands (red) and active site residues (yellow).
BtCDPS has an alpha-beta Rossmann fold. (B) Comparison to CDPS homologue structures, which superpose well by secondary structure alignment.
BtCDPS – dark blue, Rv2275 (2X9Q) – yellow, AlbC (4Q24) – light blue, YvmC-Blic (3OQI) – grey. (C) Substrate binding pockets P1 and P2. (D)
The residues of the substrate binding pockets of BtCDPS are coloured green for P1, orange for P2 and the catalytic residues are coloured yellow.
A 1,2-hexanediol bound to the substrate binding pocket of BtCDPS is shown in stick representation (pink). The deeper P1 pocket is lined with
hydrophobic residues, whereas the shallower P2 pocket has more variability in residues. Arg153 faces into the active site and make an unconventional H-
bond with the catalytic Ser33 residue. (E and F) The Electrostatic surface potential of BtCDPS mapped onto the solvent-accessible surface at a contour of
10 kcal mol1 e1 using Chimera.8 Positive charge is in blue and negative charge is in red. Two patches of positive charges exist beneath the substrate
binding pocket.
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Results and discussion
Structure of wild type BtCDPS
Thermostability is an attractive property for enzymes to possess.
Thermophilic enzymes offer simpler strategies for protein iso-
lation and regeneration,28 and have been shown to possess higher
tolerance to harsher reaction conditions, for example organic
solvents.29 As no thermostable CDPS has been characterized,
and only two have been described to date, we focused on the
CDPS from Bacillus thermoamylovorans (BtCDPS). BtCDPS shares
50% sequence identity to yvmC-BLIC from Bacillus licheniformis
(another cLL synthesising CDPS),20 and has a melting tempera-
ture of 66 1C (Fig. S8, ESI†). The crystal structure of full-length
(residues 1–232) and S33A mutant enzymes was solved at a
resolution of 1.69 Å and 1.78 Å, respectively (Fig. 1 and Fig. S13,
ESI†). BtCDPS has a single domain with an ab fold similar to
other CDPS.19–22 The structure of CDPS is highly similar to yvmC-
BLIC (RMSD 0.88 Å, over 212 residues), AlbC (RMSD 2.25, over 212
residues) and Rv2275 (RMSD 2.00 Å, over 199 residues) (Fig. 1B). A
molecule of 1,2-hexanediol co-crystallised in the P1 binding
pocket adjacent to the catalytic residues (Fig. 1D). Binding is
facilitated by a hydrogen bond contact with the side chain
carboxyl group of the catalytic Glu179 residue and other non-
bonding contacts with P1 pocket residues. The aliphatic chain of
1,2-hexanediol molecule is projected deep into the P1 pocket,
which is lined with mainly hydrophobic residues (L29, G31, L61,
A63, F112, Phe182, F183, L197), ideal to accommodate a leucine
substrate. However, the P2 pocket is far shallower and more
solvent exposed (Fig. 1C). The P2 pocket is lined with a mixture
of residues (R201, W203, K204, D148, S152, A149, R153), which is
in keeping with the previously reported sequence homology that
suggests the P2 pocket has conserved Met, Trp and Ala residues.2
Interestingly, superimposition of yvmC-BLIC on to the structure of
BtCDPS, reveals Arg153 may have a potential role in substrate
binding. The side chain of R153 is projected into the active site
and makes a strong hydrogen-bond (distance = 2.6 Å) with the
hydroxyl side chain of the catalytic serine residue, which is
unknown for this class of enzymes (Fig. 1D). Moreover, the
positioning of R153 makes it an ideal candidate to interact with
the 50-phosphate group of the aa-AMP moiety of tRNA substrate.
Intriguingly, the CHES molecule in the yvmC-BLIC complex
structure (3OQI) is positioned such that its sulphate group is in
close proximity to R153, therefore a strong bidentate ionic bond
would occur (Fig. S12, ESI†). Further examination of the crystal
structure of BtCDPS suggests that there are two patches of basic
residues on its surface (Fig. 1E and F), which could be involved in
binding to the tRNA body. Similar basic patches have also been
documented in other CDPS, such as AlbC, where mutations of the
basic residues led to decreased production of cyclodipeptides.24
Substrate tolerance for tRNA isoacceptor and amino acid
moiety
Using a coupled assay with Leucyl-tRNA synthetase to regener-
ate the Leu-tRNALeu substrates, a set of 5 leu-tRNA isoacceptors
from B. thermoamylovorans (TTA, TTG, CTA, CTC, CTG) were all
tested individually and produced similar quantities of cLL
product in the endpoint assay, suggesting BtCDPS does not
have a strong preference for the tRNA moiety (Fig. 2A). TTA,
TTG, CTC and CTG isoacceptors yielded similar amounts of cLL
products, whereas CTA produced slightly less than the others.
This result is in partial agreement with data collected for AlbC
(cFL synthesising), which demonstrated AlbC utilised different
tRNA isoacceptors with different preferences, but in that case
some isoacceptors were not tolerated. The G1–C72 pair on the
acceptor stem was proposed to be an essential element for
substrate recognition, due to the reduced activity with CTC and
TTA isoacceptors. Subsequent work has indicated a more
complex picture where different elements could be involved.1
A reduced form of aa-tRNA (a flexizyme aminoacylated mini-
tRNA including the acceptor stem) was shown to be sufficient
for cyclodipeptide synthase activity, suggesting the tRNA moiety
can be altered significantly and still accepted as a substrate.30
Additionally, only small differences were observed for the
Fig. 2 Substrate selection (A) Amount of cLL detected using an endpoint assay, monitoring BtCDPS preference for different tRNALeu isoacceptors. There
is no significant difference between tRNALeu isoacceptors. The BtCDPSS33C mutant was also similarly as active as wild type under assay conditions.
(B) Products produced by BtCDPS. Chromatogram of the extracted mass for each product. Graph shows the integrated peak area for each product.
(C) Results obtained when the assay was performed in the presence of either a single amino acid (leucine, cyclo-penta-alanine or tri-fluoroleucine) or a
mixture (cyclo-penta-alanine and trifluoroleucine). Leucine was used as a positive control in this experiment.
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activity of WT and a S33C mutant, while a larger impairment
was observed when a similar mutation was performed in
AlbC.21
By using mutant forms of tRNA synthetases (LeuRS-D345A31
and IleRS-D342A32) which lacked editing activity in our coupled
assay, we generated tRNALeu and tRNAIle substrates misami-
noacylated with either leucine, isoleucine, methionine and
valine. When using misaminoacylated substrates we detected
cLL, cII and cMM products, while cVV was not detected,
suggesting BtCDPS can accommodate and use other similar
amino acids in the active site to synthesise cyclic di-peptide
products (Fig. S10, ESI†). In addition, this result also demon-
strates BtCDPS is capable of accepting other tRNA bodies
(i.e. Leu-tRNAIle) as long as the loaded amino acid is also
tolerated.
Leucyl-tRNA synthetase has an intrinsic promiscuity for
particular unnatural leucine analogues,33 which we exploited
to investigate the scope of BtCDPS’ specificity for the amino
acid moiety of the tRNA. We swapped L-leucine for either cyclo-
penta-alanine, trifluoroleucine or both cyclo-penta-alanine and
trifluoroleucine in the cLL synthesising assay and used LC-MS
to detect product formation. BtCDPS utilised the unnatural
amino acids tested to form cyclic dipeptide products (Fig. 2B
and C and Fig. S9, ESI†), demonstrating that a degree of
promiscuity of the amino acid moiety is allowed. This is in
similar agreement to other research that also reported other
CDPS can utilise non-canonical amino acids.34
Minimalistic substrate development
Puromycin is a common aminoacyl-tRNA mimic, accepted by
the ribosome and other enzymes that bind amino-
acyl-tRNAs.35,36 We therefore synthesized leucine-puromycin
(Leu-PANS), in which the O-methyl-tyrosine amide in puromy-
cin was replaced by a leucine, to test whether this was the case
for BtCDPS. We hypothesised Leu-PANS would interact with the
substrate binding pocket. However, ITC experiments (at con-
centrations as high as 2 mM) showed no binding occurred
(Fig. S19, ESI†). In addition, we tested Leu-PANS as an inhibitor
in the aminoacylated tRNA assay, but did not observe any
inhibition of BtCDPS activity (concentrations up to 2 mM)
(Fig. S21, ESI†), supporting our ITC experiments. We predict
the ester bond linking the amino acid to the nucleotide is
playing an essential role in substrate selection in CDPS enzymes.
Combining the fact that BtCDPS does not bind Leu-PANS,
but accepts all Leu-tRNALeu isoacceptors and leucine analogues
as substrates, we proposed the minimal substrate requirements
for CDPS enzymes is an activated amino ester with a moderately
stringent selection/rejection of the amino acid side chain, while
the tRNA body plays a role in efficient substrate positioning. To
test this hypothesis, we examined amino esters of leucine
containing umbelipherone, p-nitrophenyl and dinitrobenzyl
as leaving groups (Fig. S18, ESI†) (Leu-umb, Leu-PNP, Leu-
DBE, Val-DBE and Pro-DBE, Ile-DBE and Met-DBE) as substrate
for BtCDPS.
Our results show that a cyclic dipeptide (cLL) is generated by
CDPS when Leu-DBE was used as a substrate (Fig. 3B), albeit
with low efficiency, while other leaving groups (coupled to
leucine) that were tested were not substrates. Furthermore, in
line with our experiments employing misaminoacylated tRNAs,
Ile-DBE and Met-DBE were also substrates for BtCDPS (Fig. S11,
ESI†). Addition of a dinitrobenzyl ester group to amino acids
has been extensively used as a tool to activate amino acids and
aminoacylate tRNAs, in a reaction catalysed by ribozymes of the
Flexizyme family.37,38 Both BtCDPS WT and S33C mutant
(potentially a better nucleophile, facilitating cLL production
in comparison to WT due to increased reactivity of its thioester
Fig. 3 Small molecule, Leu-DBE, is a substrate of BtCDPS (A) Reaction
scheme when utilising Leu-DBE as a substrate. (B) Leu-DBE assay depict-
ing the levels of cLL (m/z = 227.175) detected by LC-HRMS. B and C are
reactions performed overnight in the presence (+) or absence () of
Leu-DBE, using wild type (WT) or active site mutants S33A and S33C.
**** depicts significant differences between + and  experiments.
(C) Integrated DBE-OH peaks show production dependant on concen-
tration of enzyme. (D) Time course for DBE-OH formation in the presence
(half life, t1/2 = 182 min) and absence (t1/2 = 431 min) of BtCDPS. Solid line is
a fit to an exponential equation to obtain t1/2. (E) Time course for cLL
formation catalysed by wild type and S33C BtCDPS. (F) Intact mass
spectrometry of wild type BtCDPS shows the accumulation of a leucyl-
enzyme intermediate (mass increase of +115) with increasing concen-
tration of Leu-DBE substrate in assay. Accumulation is not observed when
using S33A and S33C (Fig. S16). n = 3 independent experimental replicates
for Leu-DBE assays.
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enzyme intermediate) showed a significant increase in the
amount of cLL that was detected by LC-MS, whereas the S33A
mutant was inactive. To identify the cause of low reaction
yield (78 mM cLL product formed per mM WT BtCDPS with a
Leu-tRNALeu substrate, compared to 0.8 or 2.4 mM cLL product
formed per mM WT or S33C variants, respectively), and to
confirm that Leu-DBE consumption was due to BtCDPS, we
quantified the amount of hydrolysed product (DBE-OH) over time
and in the presence and absence of increasing concentrations of
enzyme. The amount of DBE-OH formed was directly dependant
on increasing enzyme concentration (Fig. 3C). Moreover, DBE-OH
formation and Leu-DBE hydrolysis occurred at a faster rate when
BtCDPS was present (Fig. 3D and Fig. S20, respectively, ESI†). We
also observed time dependent cLL production with both BtCDPS
WT and S33C mutant (Fig. 3E).
Docking studies
We hypothesised that BtCDPS could use DBE-Leu to catalyse
the first half reaction generating the acyl enzyme intermediate
more efficiently than the second step, leading to a large
proportion of enzyme becoming trapped as an acyl form. This
could be due to improper substrate positioning to binding site
P2, which would eventually lead to acyl–enzyme hydrolysis and
a futile cycle. To test this hypothesis, we performed docking
experiments using PSOVina2 (Fig. 4). Docking of a leu-DBE
molecule was performed on the crystallographic structure of
BtCDPS (BtCDPSapo) and a model of an acyl-intermediate
(BtCDPSintermediate), which was created by superimposing PDB:
4Q24 (possesses acyl-intermediate substrate mimic (N-carbo-
benzyloxy-L-Phe-chloromethyl ketone), trimming down the
ligand atoms to convert to leucine and merging with BtCDPS.
Docking of Leu-DBE to BtCDPSapo (representing the first cata-
lytic cycle), mainly produced catalytically productive binding
poses within the top ranked DG values (Fig. 4B). These produc-
tive poses successfully place the leucine moiety into the P1
pocket with H-bonding contacts to key catalytic residues (E179,
S33 and Y175). The DBE moiety sits in the P2 pocket and the
nitro-groups H-bonds with S33, Y199, S152 and interestingly
to R153, which we speculated would interact with the AMP
50-phosphate group of aa-tRNA substrates. To validate the docking
experiment and test the importance of R153 to reactivity and
active site architecture, we produced the mutant R153A
Fig. 4 Docking of Leu-DBE to BtCDPS. Docking experiments reveal Leu-DBE binds to BtCDPS with more favourable catalytically productive poses in
the first catalytic cycle compared to the second catalytic cycle. (A) A heat map illustrating relative DG values (Pose 1 most favourable – pose 10 least
favourable) for docking of Leu-DBE to BtCDPSApo and BtCDPSIntermediate. BtCDPSIntermediate represents an acyl-intermediate enzyme state created by
superimposing PDB: 4Q24 and trimming down the ligand atoms to convert to leucine, before merging. (B) In the first catalytic cycle Leu-DBE (cyan)
docks favourably to BtCDPSapo in catalytically productive poses, represented here by pose 1. The leucine moiety places into the P1 pocket (green carbon
atoms), with the amide bond place between the catalytic residues, E179, S33 and Y175 (yellow carbon atoms). The nitro groups from DBE-Leu interact
with S33, Y199, R153 and S152. (C) Representation of the less favourable docking pose 9. The DBE moiety occupies the P1 pocket, thus the leucine moiety
is in a catalytically unproductive pose. (D) Pose 1, represents the most favourable docking pose of Leu-DBE (cyan) to BtCDPSIntermediate, which is a model
of a leucyl-S33 intermediate (purple carbon atoms) occupying the P1 pocket. The Leu-DBE molecule in pose 1 binds in a catalytically unproductive
manner. (E) The less favourable, pose 6, represents a catalytically productive binding pose of Leu-DBE to BtCDPSIntermediate. The leucine moiety sits in the
P2 pocket (residues with orange carbon atoms) and the amide bond is within hydrogen bonding distance of the catalytic residues.
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(BtCDPSR153A). Structurally BtCDPSR153A is extremely similar
to the WT BtCDPS and BtCDPSS33C. However, activity with
both Leu-tRNALeu and Leu-DBE is completely lost, supporting
our observation that this residue likely has an important
role during catalysis. Besides the loss of enzyme-substrate
interactions, the structure of BtCDPSR153A highlights R153
importance in correctly positioning the active site S33 side-
chain (Fig. S13, ESI†). The conformation of S33 sidechain is
rotated by B851, which orientates it to an inward facing
position, closer to the sidechain of Y199 (another catalytic
residue) to form an alternative H-bond in the structure of
BtCDPSR153A when compared to WT BtCDPS (2.8 Å vs. 3.5 Å).
Additionally, helix-7 is displaced (o2 Å) in the BtCDPSR153A,
due to the absence of R153.
The most productive Leu-DBE docking pose is highly similar
to the proposed aa-tRNA docking pose present in the low
resolution CDPS:aa-tRNA complex, where the terminal A76
adenosine occupies the P2 pocket.27 Docking of Leu-DBE to
the BtCDPSintermediate, which represents the second catalytic
binding event, suggests catalytically productive poses are less
favourable than non-productive poses. Leu-DBE docks loosely
to the shallower P2 pocket of BtCDPSintermediate. The less
favourable productive docking poses to BtCDPSintermediate place
the leucine moiety close to the catalytic residues and the DBE
Fig. 5 Catalytic cycle when Leu-DBE is used as a substrate. Individual panels were generated using a combination of experimental data, docking results,
and modelling based on a covalent intermediate bound to AlbC (pdb 4q24).
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moiety on the periphery of the P2 pocket. These docking
experiments support our hypothesis of an unfavourable second
catalytic step. If this was the case, a trapped acyl–enzyme
intermediate should be formed during the catalytic cycle.
Intact protein mass spectrometry
We used intact protein mass-spectrometry to analyse the state
of the protein after incubation with Leu-DBE. As we hypothe-
sized, an accumulation of the enzyme species with a mass
increase of +115 was detected, which corresponded to a trapped
acyl intermediate (Fig. 3F). This result suggests that after
completion of the first half reaction the enzyme becomes
catalytically trapped, as substrate positioning on P2 is deficient
when DBE-Leu is used as a substrate (Fig. 5). A similar mass
shift was not observed when inactive mutant S33A or catalytic
residue S33C variants were tested (Fig. S16, ESI†). A similar
mass was also absent when the reaction was conducted with a
full length aa-tRNA substrate (Fig. S17, ESI†).
These data combined suggest a role were the tRNA group of
the aa-tRNA substrate acts to efficiently position the amino acid
moiety in the binding pockets and restrict how many conformations
can be sampled by a substrate molecule. Consequently, smaller
substrates such as Leu-DBE are able to sample multiple pro-
ductive and unproductive conformations, especially when
interacting with the more open shallow P2 pocket.
Conclusions
Our work demonstrates that BtCDPS is selective for the amino
acid but less selective towards the tRNA portion of aa-tRNA
substrates. We show, for the first time, that a CDPS can use a
small molecule as a substrate to synthesise cyclic dipeptide
products rather than a conventional aa-tRNA or shorter RNAs.
Bypassing the need to generate aa-tRNA substrates for CDPS
enzymes provides an additional tool in generating cyclic dipeptide
products, not restricted by the substrate tolerance of tRNA
synthetases. Future work should now be focussed on generating
more efficient and stable small molecule substrates and enzyme
variants. Our work provides insights into the structure of a
thermophilic CDPS enzyme and identifies key residues involved
in substrate recognition. Alongside identifying a minimal sub-
strate (albeit less efficient than natural aa-tRNA), this is a perfect
informed starting point for enzyme engineering, with the inten-
tion to produce more diverse products, in an efficient simply
manner. The main requirement for successful protein design
and in vitro evolution is sufficient measurable activity, allowing
activity screens to be performed with enzyme variants, a condi-
tion fulfilled by Leu-DBE and BtCDPS.39
In a broader sense, our work highlights the fact that
throughout evolution aa-tRNA-dependent enzymes adapted to
utilize energetically expensive full length aa-tRNAs as sub-
strates as these were the molecules containing activated amino
acids amply available in the cell, without relying on non-
ribosomal peptide synthesis machineries.3,40 However, other
unnatural substrates can be used as alternatives, bypassing the
requirement of a full length tRNA. A similar situation was
observed in aminoacyl protein transferases, which transfer
amino acids to other proteins and can use small molecules as
aa-tRNA mimics.41 Here we set the foundation to developing
minimalistic aa-tRNA mimics for CDPS enzymes.
Experimental
General
Unless mentioned, all chemicals were from Sigma or Fisher
Scientific, all experiments were performed in triplicate, and all
error is reported as standard deviation.
Cloning, expression and purification
The CDPS gene from Bacillus thermoamylovorans (BtCDPS) was
synthesised as a codon optimised gBlock from IDT. The
synthesised gene was inserted into a modified pJ414 expression
plasmid (TEV-cleavable His6 protein tag) by Gibson assembly
42
cloning technique. Mutant variants of BtCDPS were produced
by site-directed mutagenesis based on the NEB Q5 site-directed
mutagenesis kit. Constructs were confirmed by sequencing and
introduced into the commercially available E. coli Bl21(DE3)
expression strain (NEB). Cells were cultured at 37 1C until the
OD600 reached 0.6; at which time protein production was
induced using 1 mM IPTG; the temperature was lowered to
18 1C and the cells continued to grow overnight.
Cell pellets were resuspended with appropriate amounts of
lysis buffer (50 mM HEPES pH 7.5, 20 mM imidazole, 250 mM
NaCl) and lysed using sonication, with centrifugation at 33 000g
(4 1C) for 30 minutes to clarify the lysate. The cell lysate was
passed through an 80 mm filter before being loaded onto a 5 ml
HisTrap HP columns (GE Healthcare) pre-equilibrated in lysis
buffer. Columns were washed with B20 column volumes of
lysis buffer and protein eluted using elution buffer (50 mM
HEPES pH 7.5, 250 mM NaCl, 400 mM imidazole). TEV protease
was added (1 : 25 ratio) to pooled elution fractions and the
sample dialysed overnight at 4 1C (in 20 mM HEPES pH 7.5,
250 mM NaCl, 5 mM b-mercaptoethanol). Cleaved protein was
separated from residual fusion protein by a second passage
over the HisTrap column. The resulting purified protein was
concentrated to B10 mg ml1 for further experiments.
Structure determination. Crystals were grown at 20 1C using
sitting drop vapour diffusion technique with drops composed
of equal volumes of protein and reservoir solution. BtCDPS
crystals were grown in 0.1 M Na Citrate pH 5.5, 37.5% PEG
550 MME, 5% 1,2-hexanediol. Crystals were cryoprotected in
mother liquor supplemented with 20% (v/v) ethylene glycol
before being flash cooled in liquid nitrogen. Diffraction data
was collected at the Diamond Light Source in Oxford, UK. Data
reduction and processing was completed using XDS and the
xia2 suite.43 The structure was solved by molecular replacement
with PHASER44 using the structure of yvmC-BLIC as a search
model (PDB: 3OQH). The other crystal forms (BtCDPSS33C and
BtCDPSR153A) were solved using the structure of WT BtCDPS as
the search model in PHASER.44 Protein structures were built/

























































































RSC Chem. Biol. ©2021 The Author(s). Published by the Royal Society of Chemistry
modified using COOT,45 with cycles of refinement in PHENIX46
and PDB-REDO.47 Crystallographic data is shown in Table S3
(ESI†).
tRNA preparation
tRNA was prepared by an in vitro transcription reaction
similarly to that described in.48 Template DNA of tRNALeu genes
from Bacillus thermoamylovorans were first amplified by PCR
using a set of primers, which included a T7 RNA promoter
sequence (Table X, ESI†). Briefly, the In vitro transcription
reaction was performed by incubating (at 37 1C for 12 hours)
the following reaction mixture: 20 mg template DNA, 20 mM
MgCl2, 50 mM HEPES pH 7.5, 2 mM Spermidine, 20 mM DTT,
5 mM ATP, 5 mM UTP, 5 mM CTP, 6 mM GTP, 5 mM RNA
polymerase D172–17349 (to ensure tRNA homogeneous 30ends).
An appropriate amount of RNAse free DNAseI was added as per
manufactures recommendations (Promega) and incubated for
1 hour at 37 1C. After incubation, samples were ran on a urea-
TBE-PAGE gel to verify tRNA production. A phenol-chloroform
extraction followed by ethanol precipitation was used to clean
up tRNA. The tRNA was resuspended in DEPC treated water and
the concentration was measured calculated from their A260
readings.
Cyclodipeptide-synthesizing activity assay
The CDPS activity of BtCDPS and variants was measured with a
coupled end-point assay, containing aaRSs (tRNA synthetase) to
maintain a continuous supply aa-tRNA substrate. The assay was
performed in a buffer containing 100 mM HEPES pH 7.5,
100 mM KCl, 20 mM MgCl2, 10 mM DTT, 5 mM ATP, 1 mM
L-Leucine, 5 mM Leucine tRNA synthetase (LeuRS), 10 mM
BtCDPS, 5 mM tRNALeu. The tRNA isoacceptors (TTG, TTA,
CTA, CTC, CTG) were assayed independently. The reaction
was carried out at 20 1C whilst mixing end-over-end. The
enzymatic reaction was initiated by the addition of BtCDPS
and quenched by the addition of an equal volume of 10%
trichloroacetic acid (TCA) and immediately boiled for 5 minutes.
The samples were then prepared for analysis by LC–MS (waters)
by centrifugation at 12 000g for 10 minutes to remove insoluble
material, and supernatant was used for analysis.
A time-course assay (using the same reaction mix as previous
stated) was used to assess cLL formation over a period of time.
The reaction was initiated by addition of 1 mM BtCDPS, and
immediately mixed well. The reaction was carried out at 20 1C,
with no further mixing. 20 ml of reaction was removed at
specific time intervals (10, 20, 40, 60 and 90 minutes) and
quenched by the addition of an equal volume of 10% trichlor-
oacetic acid (TCA) and immediately boiled for 5 minutes.
Samples were prepared for mass spectrometry analysis as
previous stated.
Assays conducted to assess BtCDPS ability to utilise mis-
aminoacylated tRNA substrates were performed following the
same procedure as for the standard cyclodipeptide-synthesizing
activity assay with minor adjustments. LeuRS-D345A or Ile-
D342A mutants (lacking editing activity) were created by site
directed mutagenesis and used in instead of LeuRS. Assays
used LeuRS-D345A or Ile-D342A paired with tRNALeu (isoacceptor
mix – TTG, TTA, CTA, CTC, CTG) and tRNAIle (isoacceptor –
ATC), respectively. Assays used 10 mM of either L-leucine, L-iso-
leucine, L-methionine or L-valine. Appropriate controls lacking
BtCDPS or tRNA were conducted in parallel.
Leu-DBE assay
Leu-DBE was chemically synthesised in house (see chemical
synthesis section in the ESI†). Leu-DBE was tested as a sub-
strate for BtCDPS in an endpoint assay. The assay was initiated
by adding 5 mM BtCDPS to a reaction mixture containing
50 mM HEPES pH 7.5, 500 mM NaCl, 5 mM DTT, 500 mM
Leu-DBE. The assay was incubated at room temperature and
agitated by end-over-end rotation over-night. The reaction was
quenched by the addition of an equal volume of 10% TCA and
boiled for 5 minutes. The precipitant was removed by centrifu-
gation at 12 000g for 10 minutes to remove insoluble material,
and supernatant was transferred to vials. The samples were
then used for analysis by LC-MS (orbitrap) or HPLC as
described below.
A Leu-DBE time-course assay, monitoring formation of cLL
at regular 40 minute timepoints over the period 0–280 minutes
(& 24 hours), to coincide with the Leu-DBE hydrolysis, HPLC
assay (see HPLC section). Samples were quenched by the
addition of TCA (100%) to a final concentration of 10% TCA.
Quenched samples were centrifuged to removed insoluble
material and diluted 50% v/v with water. Samples were analysed
using LC-MS (orbitrap).
Met-DBE and Ile-DBE were used as substrates instead of Leu-
DBE in the Leu-DBE assay to test if alternative amino
acids coupled to DBE could be used as substrates. Experiments
 1 mM Met-DBE or Ile-DBE were incubated at 20 1C for
24 hours. The reactions were quenched and prepared as stated
previously for Leu-DBE assay samples.
Cyclodipeptide detection by LC-MS
Analysis of samples using tRNA substrates was performed using
a Waters Acquity UPLC H class plus coupled to a Xevo G2-XS
QTof Quadrupole Time-of-Flight mass spectrometer. Samples
were loaded onto a Waters, ACQUITY UPLC BEH C18 Column
(130 Å, 1.7 mm, 2.1 mm  50 mm).
The LC program was as follows: 0–1 min= 1% D, 1–6 min =
linear gradient from 1–99% D, 6–9 min = 99% D, 9–12 min = D,
with a 0.4 ml min1 flow rate (D = (v/v) acetonitrile in 0.1% FA).
Data collected using the MSe mode, the mass spectrometer
was set in the electrospray positive ion mode to detect m/z in
the 100–700 Da range (scan time 0.1 s, ramp collision energy =
15–30 V, dynamic range = normal, method time = 0–12 min). A
lockspray correction by collecting every 10 s, averaging 3 scans
of 1 s each using Leucine Enkephalin (LeuEnk) as standard
(556.2771 0.56 Da). Cyclodipeptides were quantified based on
the peak area for the expected extracted mass. A cLL standard,
prepared by over-production and purification of cLL by HPLC,
was used to produce a calibration curve.
Samples from Leu-DBE, Met-DBE and Ile-DBE assays were
analysed using a Thermo Scientific Orbitrap Velos Pro with
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U3000 HPLC, with a Phenomenex Luna omega C18 column
(100 Å, 1.6 mm, 2.1 mm  50 mm). The LC program was
as follows: 0–5 min = 2% D, 5–10 min = linear gradient
from 2–70% D, 10–10.5 min = linear gradient from 70–99%
D, 10.5–13 min = 99% D, 13–13.1 min = 2% D, 13.1–15 min =
2% D, with a flow rate of 0.2 ml min1 (D = (v/v) acetonitrile in
0.1% FA).
MS data collected throughout the 15 min LC run with the
following settings: polarity = positive, analyzer = FTMS, mass
range = normal, resolution = 15 000, scan range = 200–500 Da
range m/z. Cyclodipeptides were quantified as previously
stated above.
Cyclodipeptide detection by HPLC
HPLC analysis was performed using a Shimadzu Prominence
UFLC, HPLC coupled to a Shimadzu ELSD-LT II detector, to
detect and collect cLL from assay samples. The samples were
loaded onto a C18 column (NUCLEODUR 100-5 C18 250 
4.6 mm), run with a linear gradient from 0.5% to 100% (v/v)
acetonitrile in 0.1% (v/v) TFA, at a flow rate of 1 ml min1. The
program was as follows:
0–5 min, 0.5% (v/v) acetonitrile in 0.1% (v/v) TFA 5–40 min,
linear gradient from 20–80% (v/v) acetonitrile in 0.1% (v/v) TFA,
40–45 min, 99% (v/v) acetonitrile in 0.1% (v/v) TFA, 45–50 min,
1% (v/v) acetonitrile in 0.1% (v/v) TFA.
Absorbance was monitored at 220 nm wavelength and with
the ELSD detector (temperature 40 1C, gain 12). For extraction
of cLL, peaks with a retention time of 24 min, were collected by
a Shimadzu FRC-10A fraction collector. Collected peak frac-
tions were pooled and freeze dried to remove liquid and
resuspended in 50/50 water/DMSO. The sample was then
checked using HRMS and quantified using the absorbance
reading at 215 nm on a DeNovix DS-11 FX spectrophotometer
on peptide mode (e0.1% = 11.7).
HPLC was also used to measure hydrolysis of Leu-DBE in the
presence of different concentrations of BtCDPS. Leu-DBE
and DBE-OH standards had retention times of 19.5 min and
21 min, respectively. Leu-DBE has a half-life of 431 min in our
assay conditions (Fig. S20, ESI†), and therefore Leu-DBE
standards were run immediately after resuspension in water
to reduce the hydrolysis associated with long term storage
in water.
HPLC was used to analyse hydrolysis of Leu-DBE and
formation of DBE-OH from our Leu-DBE time-course assay
(same reaction materials as previously stated, 50 mM of enzyme
used in reaction). Hydrolysis of Leu-DBE occurs spontaneously
in water, so reactions were quenched at regular 40 minute
intervals from 0–280 minutes (& 24 hours), to coincide with the
HPLC run time. Samples were quenched by the addition of TCA
(100%) to a final concentration of 10% TCA. Quenched samples
were immediately vortexed and centrifuged for 2 minutes to
remove insoluble material. 50 ml of samples were immediately
injected onto the HPLC.
Concentration was calculated as follows: 1 mM = (peak
area corresponding to DBE-Leu + peak area corresponding to
DBE-OH).
Identification of the covalent peptidyl-enzyme intermediate
Acyl-intermediate enzyme preparation was performed by incu-
bating 20 mM enzyme with excess Leu-DBE (500 mM or 2.5 mM),
for 2 h or overnight by end-over-end rotation. The samples were
then sent for analysis at the University of St Andrews mass
spectrometry and proteomics facility. The method for analysis
was as follows:
20 ml of sample at 1 : 20 dilution, was injected onto a Waters
MassPrep micro column 2 mm  5 mm on a Waters Xevo
LC-MS system optimised for protein analysis. A short gradient
elution was used to desalt and then elute the protein as follows:
Time (min) Flow Rate (ml min1) %A = 98% water (1%FA) 2%
Acetonitrile %B = 98% acetonitrile (1%FA) 2% water.
(1) Initial 0.200 98.0 2.0.
(2) 0.50 0.200 98.0 2.0.
(3) 3.80 0.200 2.0 98.0.
(4) 4.50 0.200 2.0 98.0.
(5) 4.60 0.200 100.0 0.0.
(6) 5.00 0.200 100.0 0.0.
The MS was operated in ESI+ and scanned from 500–2500 m/z
with lock mass of LeuEnk as described above under ‘‘Cyclo-
dipeptide detection by LC-MS’’. The protein spectrum elution at
3 minutes was combined and the raw data processes to mass
using MaxEnt algorithm at 0.1 resolution using peak width of
half height of 0.4 Da.
Chemical synthesis of Leu-PANS, Leu-cou, Leu-DBE, Val-DBE,
Ile-DBE and Met-DBE)
Chemical synthesis of aa-DBE compounds were carried out
following the procedures described by Peacock JR, et al.50
Detailed procedures are on the ESI.† NMR was used to verify
aa-DBE compounds identity and purity (Fig. S3–S7, ESI†).
Chemical synthesis of Leu-Puromycin and Leu-Coumarin
were carried out following a modification of the procedures
described by Stark et al.,51 and a detailed description of
methods, NMR and HRMS is available on the ESI.†
Ligand docking
The ligand Leucine-DBE was docked into the CDPS protein
(PDB:6ZTU) as an apo-enzyme (CDPSapo) and an acyl–enzyme
model (BtCDPSintermediate), generated by superimposition and
trimming of the ligand from PDB: 4Q24 (N-carbobenzyloxy-L-
Phe-chloromethyl ketone), using PSOVina2.52 First, water
molecules and other heteroatoms were removed from the struc-
ture, and the program PDB2PQR 2.1.153 used to assign position-
optimized hydrogen atoms, utilizing the additional PropKa2
algorithm54 with a pH of 7.4 to predict protonation states. The
MGLTools 1.5.6 utility55 prepare_receptor4.py was used to assign
Gasteiger charges to atoms. Hydrogen atoms were assigned to
compound structures using OpenBabel 2.4.1,56 utilizing the -p
option to predict the protonation states of functional groups at
pH 7.4. The MGLTools utility prepare_ligand4.py was used to
assign Gasteiger charges and rotatable bonds. PSOVina2 was
used to automatically dock the compounds into the second
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ligand-binding site of the crystal structures. A grid box that
encompassed the maximum dimensions of the ligand plus
12 Å in each direction was used. The starting translation and
orientation of the ligand and the torsion angles of all rotatable
bonds were set to random.
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